NASDAQ:AKRX - Akorn Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $17.31 +0.46 (+2.73 %) (As of 07/19/2018 04:00 PM ET)Previous Close$16.85Today's Range$16.65 - $17.3752-Week Range$10.76 - $33.72Volume1.84 million shsAverage Volume2.59 million shsMarket Capitalization$2.10 billionP/E Ratio10.40Dividend YieldN/ABeta1.67 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois. Receive AKRX News and Ratings via Email Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:AKRX CUSIP00972810 Webwww.akorn.com Phone847-279-6100 Debt Debt-to-Equity Ratio1.01 Current Ratio4.64 Quick Ratio3.37 Price-To-Earnings Trailing P/E Ratio10.40 Forward P/E Ratio61.82 P/E Growth2.63 Sales & Book Value Annual Sales$841.04 million Price / Sales2.58 Cash Flow$0.5443 per share Price / Cash31.80 Book Value$6.65 per share Price / Book2.60 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-24,550,000.00 Net Margins-12.22% Return on Equity-9.63% Return on Assets-4.20% Miscellaneous Employees2,308 Outstanding Shares125,260,000Market Cap$2,096.83 Akorn (NASDAQ:AKRX) Frequently Asked Questions What is Akorn's stock symbol? Akorn trades on the NASDAQ under the ticker symbol "AKRX." How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. The company had revenue of $280.70 million for the quarter, compared to analyst estimates of $272.99 million. Akorn had a negative return on equity of 9.63% and a negative net margin of 12.22%. The company's quarterly revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History. What price target have analysts set for AKRX? 6 brokers have issued twelve-month target prices for Akorn's shares. Their forecasts range from $14.00 to $34.00. On average, they anticipate Akorn's share price to reach $28.20 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View Analyst Ratings for Akorn. What is the consensus analysts' recommendation for Akorn? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Akorn's key competitors? Some companies that are related to Akorn include Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), United Therapeutics (UTHR), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO) and Ultragenyx Pharmaceutical (RARE). Who are Akorn's key executives? Akorn's management team includes the folowing people: Mr. Rajat Rai, Chief Exec. Officer (Age 51)Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55) Has Akorn been receiving favorable news coverage? Headlines about AKRX stock have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a news sentiment score of 0.05 on Accern's scale. They also assigned news articles about the company an impact score of 45.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are Akorn's major shareholders? Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Havens Advisors LLC (0.19%), Municipal Employees Retirement System of Michigan (0.02%) and Amalgamated Bank (0.01%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Kenneth Abramowitz. View Institutional Ownership Trends for Akorn. Which institutional investors are selling Akorn stock? AKRX stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan and Amalgamated Bank. Company insiders that have sold Akorn company stock in the last year include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Insider Buying and Selling for Akorn. Which institutional investors are buying Akorn stock? AKRX stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC. View Insider Buying and Selling for Akorn. How do I buy shares of Akorn? Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akorn's stock price today? One share of AKRX stock can currently be purchased for approximately $17.31. How big of a company is Akorn? Akorn has a market capitalization of $2.10 billion and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe. How can I contact Akorn? Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected] MarketBeat Community Rating for Akorn (NASDAQ AKRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 419 (Vote Outperform)Underperform Votes: 347 (Vote Underperform)Total Votes: 766MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?